Telix Pharmaceuticals Ltd (ASX: TLX) has established Telix Pharmaceuticals (Japan) Ltd and has appointed the first two members of the Japanese leadership team, the Australian biopharmaceutical company announced on Monday.

Telix Japan is a wholly-owned operating subsidiary of Telix Pharmaceuticals Ltd, the purpose of which is to support the company's Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in Japan.

The company has appointed Dr Shintaro Nishimura and Dr Takeshi Oka as president and chief operating officer, and chief medical officer in Japan, respectively.

Telix co-founder and CEO, Dr Christian Behrenbruch, highlighted the importance of the Japanese market for Telix's products, noting that the company's activities cover a range of "manufacturing and collaboration activities with leading Japanese clinical sites and biopharmaceutical companies."

Telix focuses on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), aiming to provide oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.